Atara Non Current Assets Total from 2010 to 2024

ATRA Stock  USD 0.71  0.01  1.39%   
Atara Biotherapeutics' Non Current Assets Total are increasing over the years with slightly volatile fluctuation. Overall, Non Current Assets Total are expected to go to about 98.2 M this year. Non Current Assets Total is the total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets. View All Fundamentals
 
Non Current Assets Total  
First Reported
2013-12-31
Previous Quarter
74.1 M
Current Value
70.1 M
Quarterly Volatility
34.7 M
 
Yuan Drop
 
Covid
Check Atara Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Atara main balance sheet or income statement drivers, such as Interest Expense of 3.8 M, Selling General Administrative of 51.5 M or Other Operating Expenses of 202.9 M, as well as many exotic indicators such as Price To Sales Ratio of 5.75, Dividend Yield of 0.0032 or Operating Cycle of 256. Atara financial statements analysis is a perfect complement when working with Atara Biotherapeutics Valuation or Volatility modules.
  
This module can also supplement Atara Biotherapeutics' financial leverage analysis and stock options assessment as well as various Atara Biotherapeutics Technical models . Check out the analysis of Atara Biotherapeutics Correlation against competitors.
For information on how to trade Atara Stock refer to our How to Trade Atara Stock guide.

Latest Atara Biotherapeutics' Non Current Assets Total Growth Pattern

Below is the plot of the Non Current Assets Total of Atara Biotherapeutics over the last few years. It is the total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets. Atara Biotherapeutics' Non Current Assets Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Atara Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
Non Current Assets Total10 Years Trend
Slightly volatile
   Non Current Assets Total   
       Timeline  

Atara Non Current Assets Total Regression Statistics

Arithmetic Mean40,756,003
Geometric Mean3,624,656
Coefficient Of Variation99.90
Mean Deviation37,505,736
Median45,589,000
Standard Deviation40,714,551
Sample Variance1657.7T
Range98.2M
R-Value0.94
Mean Square Error217.3T
R-Squared0.88
Slope8,531,923
Total Sum of Squares23207.4T

Atara Non Current Assets Total History

202498.2 M
202393.5 M
202281.3 M
202183.5 M
202064.8 M
201970 M
201870.3 M

About Atara Biotherapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Atara Biotherapeutics income statement, its balance sheet, and the statement of cash flows. Atara Biotherapeutics investors use historical funamental indicators, such as Atara Biotherapeutics's Non Current Assets Total, to determine how well the company is positioned to perform in the future. Although Atara Biotherapeutics investors may use each financial statement separately, they are all related. The changes in Atara Biotherapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Atara Biotherapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Atara Biotherapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Atara Biotherapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2024
Non Current Assets Total93.5 M98.2 M

Pair Trading with Atara Biotherapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Atara Biotherapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Atara Biotherapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Atara Stock

  0.6CALT Calliditas Therapeutics Financial Report 21st of May 2024 PairCorr
  0.57PFE Pfizer Inc Fiscal Quarter End 31st of March 2024 PairCorr
  0.52VALN Valneva SE ADR Financial Report 2nd of May 2024 PairCorr
  0.52MGTX MeiraGTx Holdings PLC Financial Report 9th of May 2024 PairCorr
  0.49CVS CVS Health Corp Financial Report 1st of May 2024 PairCorr
The ability to find closely correlated positions to Atara Biotherapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Atara Biotherapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Atara Biotherapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Atara Biotherapeutics to buy it.
The correlation of Atara Biotherapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Atara Biotherapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Atara Biotherapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Atara Biotherapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Atara Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Atara Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Atara Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Atara Biotherapeutics Stock:
Check out the analysis of Atara Biotherapeutics Correlation against competitors.
For information on how to trade Atara Stock refer to our How to Trade Atara Stock guide.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Complementary Tools for Atara Stock analysis

When running Atara Biotherapeutics' price analysis, check to measure Atara Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atara Biotherapeutics is operating at the current time. Most of Atara Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Atara Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atara Biotherapeutics' price. Additionally, you may evaluate how the addition of Atara Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
CEOs Directory
Screen CEOs from public companies around the world
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Is Atara Biotherapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atara Biotherapeutics. If investors know Atara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Atara Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.78)
Revenue Per Share
0.043
Quarterly Revenue Growth
(0.52)
Return On Assets
(0.64)
Return On Equity
(4.26)
The market value of Atara Biotherapeutics is measured differently than its book value, which is the value of Atara that is recorded on the company's balance sheet. Investors also form their own opinion of Atara Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Atara Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atara Biotherapeutics' market value can be influenced by many factors that don't directly affect Atara Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atara Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Atara Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atara Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.